{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:51:38Z","timestamp":1774954298882,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fundamental Research Grant Scheme by Ministry of Higher Education Malaysia","award":["FRGS\/1\/2019\/SKK08\/UKM\/03\/6"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK08\/UKM\/03\/6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11718-w","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:52:39Z","timestamp":1774950759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating chemoresistance in triple-negative breast cancer: interplay between molecular signalling pathways and immune microenvironment"],"prefix":"10.1007","volume":"53","author":[{"given":"Ezanee Azlina","family":"Mohamad Hanif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afreena Afiqah","family":"Azman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena Rahayu","family":"Md Zin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"11718_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9781119000822.hfcm002","volume":"01","author":"D Hanahan","year":"2017","unstructured":"Hanahan D, Robert AW (2017) Biological Hallmarks of cancer. Holland-Frei cancer Med 01:1\u201310. https:\/\/doi.org\/10.1002\/9781119000822.hfcm002","journal-title":"Holland-Frei cancer Med"},{"key":"11718_CR2","doi-asserted-by":"publisher","unstructured":"Celi\u00e0-terrassa T, Kang Y (2016) Distinctive properties of metastasis- initiating cells. Genes Dev 892\u2013908. https:\/\/doi.org\/10.1101\/gad.277681.116.892","DOI":"10.1101\/gad.277681.116.892"},{"key":"11718_CR3","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.breast.2015.07.009","volume":"24","author":"BD Lehmann","year":"2015","unstructured":"Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24:S36\u2013S40. https:\/\/doi.org\/10.1016\/j.breast.2015.07.009","journal-title":"Breast"},{"key":"11718_CR4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014","journal-title":"J Clin Invest"},{"key":"11718_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195524","author":"O Stanowska","year":"2022","unstructured":"Stanowska O, Kuczkiewicz-Siemion O, D\u0119bowska M et al (2022) PD-L1-positive high-grade triple-negative breast cancer patients respond better to standard neoadjuvant treatment\u2014a retrospective study of pd-l1 expression in relation to different clinicopathological parameters. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11195524","journal-title":"J Clin Med"},{"key":"11718_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"11718_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14694\/EDBK_159135","volume":"36","author":"CK Anders","year":"2016","unstructured":"Anders CK, Abramson V, Tan T, Dent R (2016) The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. Am Soc Clin Oncol Educational Book 36:34\u201342. https:\/\/doi.org\/10.14694\/EDBK_159135","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"11718_CR8","doi-asserted-by":"publisher","unstructured":"Bertheau P, Lehmann-Che J, Varna M et al (2013) P53 in Breast Cancer Subtypes and New Insights Into Response To Chemotherapy. Breast (Edinburgh, Scotland) 22 Suppl. 2S27\u2013S29. https:\/\/doi.org\/10.1016\/j.breast.2013.07.005","DOI":"10.1016\/j.breast.2013.07.005"},{"key":"11718_CR9","doi-asserted-by":"publisher","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","volume":"2","author":"M Oren","year":"2010","unstructured":"Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2:a001107. https:\/\/doi.org\/10.1101\/cshperspect.a001107","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"11718_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.humpath.2015.05.010","volume":"46","author":"MH Jang","year":"2015","unstructured":"Jang MH, Kim HJ, Kim EJ et al (2015) Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol 46:1267\u20131274. https:\/\/doi.org\/10.1016\/j.humpath.2015.05.010","journal-title":"Hum Pathol"},{"key":"11718_CR11","doi-asserted-by":"publisher","unstructured":"Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (Edinburgh, Scotland) 24 Suppl. 2S36\u201340. https:\/\/doi.org\/10.1016\/j.breast.2015.07.009","DOI":"10.1016\/j.breast.2015.07.009"},{"key":"11718_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11070911","volume":"11","author":"S Romero-Cordoba","year":"2019","unstructured":"Romero-Cordoba S, Meneghini E, Sant M et al (2019) Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation. Cancers (Basel) 11:1\u201320. https:\/\/doi.org\/10.3390\/cancers11070911","journal-title":"Cancers (Basel)"},{"key":"11718_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li M, Jiang Z, Wang X (2018) A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Transl Oncol 11:311\u2013329. https:\/\/doi.org\/10.1016\/j.tranon.2018.01.011","journal-title":"Transl Oncol"},{"key":"11718_CR14","doi-asserted-by":"publisher","unstructured":"Izadi A, Naimi A, Amjadi E et al (2024) The Prevalence of PD-L1 Expression in Triple-Negative Breast Cancer Patients and Its Correlation with Survival Rates and Other Prognostic Factors: A Survival Analysis. Adv Biomed Res 13. https:\/\/doi.org\/10.4103\/abr.abr_2_24","DOI":"10.4103\/abr.abr_2_24"},{"key":"11718_CR15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.31557\/APJCP.2022.23.3.1091","volume":"23","author":"NH Amin","year":"2022","unstructured":"Amin NH, Abou-Bakr AA, Eissa S et al (2022) Expression of PD-L1 in Early-Stage Invasive Breast Carcinoma and Its Relation to Tumor-Infiltrating Lymphocytes. Asian Pac J Cancer Prev 23:1091\u20131102. https:\/\/doi.org\/10.31557\/APJCP.2022.23.3.1091","journal-title":"Asian Pac J Cancer Prev"},{"key":"11718_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00470","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen M, Wang J, Ren X (2018) New insights into tumor-infiltrating B lymphocytes in breast cancer: Clinical impacts and regulatory mechanisms. Front Immunol 9:1\u20138. https:\/\/doi.org\/10.3389\/fimmu.2018.00470","journal-title":"Front Immunol"},{"key":"11718_CR17","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS (2016) Immune escape to PD-L1\/PD-1 blockade: Seven steps to success (or failure). Ann Oncol 27:1492\u20131504. https:\/\/doi.org\/10.1093\/annonc\/mdw217","journal-title":"Ann Oncol"},{"key":"11718_CR18","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.18632\/oncotarget.7235","volume":"7","author":"M Black","year":"2016","unstructured":"Black M, Barsoum IB, Truesdell P et al (2016) Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 7:10557\u201310567. https:\/\/doi.org\/10.18632\/oncotarget.7235","journal-title":"Oncotarget"},{"key":"11718_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/narcan\/zcaa002","volume":"2","author":"C Bailly","year":"2020","unstructured":"Bailly C, Thuru X, Quesnel B (2020) Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer 2:1\u201320. https:\/\/doi.org\/10.1093\/narcan\/zcaa002","journal-title":"NAR Cancer"},{"key":"11718_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1017\/CBO9781107415324.004","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D et al (2018) A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell 174:1373\u20131387. https:\/\/doi.org\/10.1017\/CBO9781107415324.004","journal-title":"Cell"},{"key":"11718_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1263412","volume":"6","author":"MZ Noman","year":"2017","unstructured":"Noman MZ, Janji B, Abdou A et al (2017) The immune checkpoint ligand PD-l1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. OncoImmunology 6:1\u20137. https:\/\/doi.org\/10.1080\/2162402X.2016.1263412","journal-title":"OncoImmunology"},{"key":"11718_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11071033","volume":"11","author":"G Planes-Laine","year":"2019","unstructured":"Planes-Laine G, Rochigneux P, Bertucci F et al (2019) PD-1\/PD-l1 targeting in breast cancer: The first clinical evidences are emerging. a literature review. Cancers 11:1\u201325. https:\/\/doi.org\/10.3390\/cancers11071033","journal-title":"Cancers"},{"key":"11718_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcancer.2017.12.008","volume":"52","author":"L Agrawal","year":"2018","unstructured":"Agrawal L, Engel KB, Greytak SR, Moore HM (2018) Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Sem Cancer Biol 52:26\u201338. https:\/\/doi.org\/10.1016\/j.semcancer.2017.12.008","journal-title":"Sem Cancer Biol"},{"key":"11718_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421. https:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"key":"11718_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bjc.2016.17","volume":"114","author":"JH Park","year":"2016","unstructured":"Park JH, Powell AG, Roxburgh CSD et al (2016) Mismatch repair status in patients with primary operable colorectal cancer: Associations with the local and systemic tumour environment. Br J Cancer 114:562\u2013570. https:\/\/doi.org\/10.1038\/bjc.2016.17","journal-title":"Br J Cancer"},{"key":"11718_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"key":"11718_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D et al (2019) Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - Results of a prospective biomarker study. J Immunother Cancer 7:1\u201315. https:\/\/doi.org\/10.1186\/s40425-019-0659-0","journal-title":"J Immunother Cancer"},{"key":"11718_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-61710-y","volume":"10","author":"J Mei","year":"2020","unstructured":"Mei J, Zhao J, Fu Y (2020) Molecular classification of breast cancer using the mRNA expression profiles of immune-related genes. Sci Rep 10:1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-61710-y","journal-title":"Sci Rep"},{"key":"11718_CR29","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","volume":"26","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Keenan TE, Pernas S et al (2020) Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1\/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 26:2565\u20132572. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3507","journal-title":"Clin Cancer Res"},{"key":"11718_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1490854","volume":"7","author":"A Thomas","year":"2018","unstructured":"Thomas A, Routh ED, Pullikuth A et al (2018) Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology 7:1\u201312. https:\/\/doi.org\/10.1080\/2162402X.2018.1490854","journal-title":"OncoImmunology"},{"key":"11718_CR31","first-page":"1","volume":"11","author":"JC Mej\u00eda-G\u00f3mez","year":"2020","unstructured":"Ernesto Rojas-Jim\u00e9nez, Mej\u00eda-G\u00f3mez JC et al (2020) Clara D\u00edaz-Vel\u00e1squez, comprehensive genomic profile of heterogeneous. Genes 11:1\u201321","journal-title":"Genes"},{"key":"11718_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7717\/peerj.6501","volume":"2019","author":"S Niyomnaitham","year":"2019","unstructured":"Niyomnaitham S, Parinyanitikul N, Roothumnong E et al (2019) Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. PeerJ 2019:1\u201317. https:\/\/doi.org\/10.7717\/peerj.6501","journal-title":"PeerJ"},{"key":"11718_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0238262","volume":"15","author":"A Philipovskiy","year":"2020","unstructured":"Philipovskiy A, Dwivedi AK, Gamez R et al (2020) Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. PLoS ONE 15:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0238262","journal-title":"PLoS ONE"},{"key":"11718_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Liu Y, Xiao Y et al (2021) Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 31:178\u2013186. https:\/\/doi.org\/10.1038\/s41422-020-0375-9","journal-title":"Cell Res"},{"key":"11718_CR35","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.7150\/thno.36182","volume":"10","author":"F Coussy","year":"2020","unstructured":"Coussy F, Lavigne M, de Koning L et al (2020) Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics 10:1531\u20131543. https:\/\/doi.org\/10.7150\/thno.36182","journal-title":"Theranostics"},{"key":"11718_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55710-w","volume":"9","author":"DY Wang","year":"2019","unstructured":"Wang DY, Jiang Z, Ben-David Y et al (2019) Molecular stratification within triple-negative breast cancer subtypes. Sci Rep 9:1\u201310. https:\/\/doi.org\/10.1038\/s41598-019-55710-w","journal-title":"Sci Rep"},{"key":"11718_CR37","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014DS1","volume":"121","author":"BDB Lehmann","year":"2011","unstructured":"Lehmann BDB, Bauer Ja, Chen J X, et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014DS1","journal-title":"J Clin Invest"},{"key":"11718_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:1\u201313. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"11718_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","volume":"29","author":"Y Bareche","year":"2018","unstructured":"Bareche Y, Venet D, Ignatiadis M et al (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29:895\u2013902. https:\/\/doi.org\/10.1093\/annonc\/mdy024","journal-title":"Ann Oncol"},{"key":"11718_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C et al (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell 35:428\u2013440e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.001","journal-title":"Cancer Cell"},{"key":"11718_CR41","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK et al (2019) Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest 129:1785\u20131800. https:\/\/doi.org\/10.1172\/JCI96313","journal-title":"J Clin Invest"},{"key":"11718_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0204513","volume":"13","author":"K Harano","year":"2018","unstructured":"Harano K, Wang Y, Lim B et al (2018) Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE 13:1\u20138. https:\/\/doi.org\/10.1371\/journal.pone.0204513","journal-title":"PLoS ONE"},{"key":"11718_CR43","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3892\/ol.2020.11381","volume":"19","author":"J Cheng","year":"2020","unstructured":"Cheng J, Ding X, Xu S et al (2020) Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors. Oncol Lett 19:2817\u20132824. https:\/\/doi.org\/10.3892\/ol.2020.11381","journal-title":"Oncol Lett"},{"key":"11718_CR44","first-page":"2605","volume":"51","author":"AM Davidoff","year":"1991","unstructured":"Davidoff AM, Kerns BM, Iglehart JD, Marks JR (1991) Maintenance of p53 Alterations throughout Breast Cancer Progression Maintenance of p53 Alterations throughout Breast Cancer Progression1. Cancer Res 51:2605\u20132610","journal-title":"Cancer Res"},{"key":"11718_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ctrv.2012.12.001","volume":"39","author":"N Turner","year":"2013","unstructured":"Turner N, Moretti E, Siclari O et al (2013) Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 39:541\u2013550. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.001","journal-title":"Cancer Treat Rev"},{"key":"11718_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.molonc.2012.03.003","volume":"6","author":"C Piovan","year":"2012","unstructured":"Piovan C, Palmieri D, Di Leva G et al (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6:458\u2013472. https:\/\/doi.org\/10.1016\/j.molonc.2012.03.003","journal-title":"Mol Oncol"},{"key":"11718_CR47","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.critrevonc.2013.05.003","volume":"88","author":"I Shapira","year":"2013","unstructured":"Shapira I, Lee A, Vora R, Budman DR (2013) P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Crit Rev Oncol\/Hematol 88:284\u2013292. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.05.003","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"11718_CR48","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.breast.2013.05.012","volume":"22","author":"Z Elsawaf","year":"2013","unstructured":"Elsawaf Z, Sinn H-P, Rom J et al (2013) Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast (Edinburgh Scotland) 22:986\u2013992. https:\/\/doi.org\/10.1016\/j.breast.2013.05.012","journal-title":"Breast (Edinburgh Scotland)"},{"key":"11718_CR49","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.15252\/emmm.201404402","volume":"6","author":"JC Liu","year":"2014","unstructured":"Liu JC, Voisin V, Wang S et al (2014) Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med 6:1542\u20131560. https:\/\/doi.org\/10.15252\/emmm.201404402","journal-title":"EMBO Mol Med"},{"key":"11718_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr1749","volume":"9","author":"M Taylor","year":"2007","unstructured":"Taylor M, Bolton LM, Johnson P et al (2007) Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res 9:1\u20137. https:\/\/doi.org\/10.1186\/bcr1749","journal-title":"Breast Cancer Res"},{"key":"11718_CR51","doi-asserted-by":"publisher","DOI":"10.17795\/ijcp-4993","author":"Z Taherian-Esfahani","year":"2016","unstructured":"Taherian-Esfahani Z, Abedin-Do A, Nikpayam E et al (2016) Cancer-testis antigens: A novel group of tumor biomarkers in ovarian cancers. Int J Cancer Manage. https:\/\/doi.org\/10.17795\/ijcp-4993","journal-title":"Int J Cancer Manage"},{"key":"11718_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.canlet.2017.02.031","volume":"399","author":"Y Li","year":"2017","unstructured":"Li Y, Li J, Wang Y et al (2017) Roles of cancer\/testis antigens (CTAs) in breast cancer. Cancer Lett 399:64\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.031","journal-title":"Cancer Lett"},{"key":"11718_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040740","author":"P Kulkarni","year":"2017","unstructured":"Kulkarni P, Uversky VN (2017) Cancer\/testis antigens: smart biomarkers for diagnosis and prognosis of prostate and other cancers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18040740","journal-title":"Int J Mol Sci"},{"key":"11718_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/CBO9781107415324.004","volume":"3","author":"RJ Seager","year":"2017","unstructured":"Seager RJ, Hajal C, Spill F et al (2017) Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg Sci Phys Oncol 3:1\u201334. https:\/\/doi.org\/10.1017\/CBO9781107415324.004","journal-title":"Converg Sci Phys Oncol"},{"key":"11718_CR55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","volume":"4","author":"ZA Gibbs","year":"2018","unstructured":"Gibbs ZA, Whitehurst AW (2018) Emerging Contributions of Cancer\/Testis Antigens to Neoplastic Behaviors. Trends Cancer 4:701\u2013712. https:\/\/doi.org\/10.1016\/j.trecan.2018.08.005","journal-title":"Trends Cancer"},{"key":"11718_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li M, Jiang Z, Wang X (2018) A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Translational Oncol 11:311\u2013329. https:\/\/doi.org\/10.1016\/j.tranon.2018.01.011","journal-title":"Translational Oncol"},{"key":"11718_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mgg3.1001","volume":"7","author":"M Behring","year":"2019","unstructured":"Behring M, Vazquez AI, Cui X et al (2019) Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages. Mol Genet Genomic Med 7:1\u20139. https:\/\/doi.org\/10.1002\/mgg3.1001","journal-title":"Mol Genet Genomic Med"},{"key":"11718_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers11010004","volume":"11","author":"S Yamamoto","year":"2019","unstructured":"Yamamoto S, Iwakuma T (2019) Regulators of oncogenic mutant TP53 gain of function. Cancers 11:15\u201321. https:\/\/doi.org\/10.3390\/cancers11010004","journal-title":"Cancers"},{"key":"11718_CR59","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-19-1131","volume":"25","author":"A Matikas","year":"2019","unstructured":"Matikas A, Zerdes I, L\u00f6vrot J et al (2019) Prognostic implications of PD-L1 expression in breast cancer: Systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. Clin Cancer Res 25:5717\u20135726. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1131","journal-title":"Clin Cancer Res"},{"key":"11718_CR60","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.2147\/OTT.S209484","volume":"12","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Wang CL, Xian J et al (2019) Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer. OncoTargets Therapy 12:7193\u20137201. https:\/\/doi.org\/10.2147\/OTT.S209484","journal-title":"OncoTargets Therapy"},{"key":"11718_CR61","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10753-013-9621-3","volume":"36","author":"CJ Ferrante","year":"2013","unstructured":"Ferrante CJ, Pinhal-Enfield G, Elson G et al (2013) The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4R\u03b1) signaling. Inflammation 36:921\u2013931. https:\/\/doi.org\/10.1007\/s10753-013-9621-3","journal-title":"Inflammation"},{"key":"11718_CR62","doi-asserted-by":"publisher","unstructured":"Trujillo JA, Sweis RF, Bao R, Luke JJ (2018). T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework For Cancer Immunotherapy Drug Development and Combination Therapy Selection 6 (9): 990\u20131000. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0277.T","DOI":"10.1158\/2326-6066.CIR-18-0277.T"},{"key":"11718_CR63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/jphp.12844","volume":"70","author":"A Bahreyni","year":"2018","unstructured":"Bahreyni A, Khazaei M, Rajabian M et al (2018) Therapeutic potency of pharmacological adenosine receptor agonist\/antagonist in angiogenesis, current status and perspectives. J Pharm Pharmacol 70:191\u2013196. https:\/\/doi.org\/10.1111\/jphp.12844","journal-title":"J Pharm Pharmacol"},{"key":"11718_CR64","doi-asserted-by":"publisher","first-page":"34554","DOI":"10.18632\/oncotarget.26177","volume":"9","author":"E Horigome","year":"2018","unstructured":"Horigome E, Fujieda M, Handa T et al (2018) Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling. Oncotarget 9:34554\u201334566. https:\/\/doi.org\/10.18632\/oncotarget.26177","journal-title":"Oncotarget"},{"key":"11718_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X (2018) Classification of triple-negative breast cancers based on Immunogenomic profiling. J Experimental Clin Cancer Res 37:1\u201313. https:\/\/doi.org\/10.1186\/s13046-018-1002-1","journal-title":"J Experimental Clin Cancer Res"},{"key":"11718_CR66","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10495-012-0707-4","volume":"17","author":"P Warrener","year":"2012","unstructured":"Warrener P, Kim S, Williams SMG et al (2012) Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-\u03b3. Apoptosis: Int J Program cell death 17:691\u2013701. https:\/\/doi.org\/10.1007\/s10495-012-0707-4","journal-title":"Apoptosis: Int J Program cell death"},{"key":"11718_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/CBO9781107415324.004","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H et al (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23:1\u201319. https:\/\/doi.org\/10.1017\/CBO9781107415324.004","journal-title":"Clin Cancer Res"},{"key":"11718_CR68","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1093\/annonc\/mdr621","volume":"23","author":"aMM Oonk","year":"2012","unstructured":"Oonk aMM, van Rijn C, Smits MM et al (2012) Clinical correlates of BRCAness in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Annals oncology: official J Eur Soc Med Oncol \/ ESMO 23:2301\u20132305","journal-title":"Annals oncology: official J Eur Soc Med Oncol \/ ESMO"},{"key":"11718_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0215381","volume":"14","author":"WX Wen","year":"2019","unstructured":"Wen WX, Leong CO (2019) Association of BRCA1- And BRCA2-deficiency with mutation burden, expression of PD-L1\/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE 14:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0215381","journal-title":"PLoS ONE"},{"key":"11718_CR70","doi-asserted-by":"publisher","unstructured":"Kalinski P, Talmadge JE (2017) Tumor immune microenvironment in cancer progression and cancer therapy. Adv Exp Med Biol. 1036: 1\u201318 https:\/\/doi.org\/10.1007\/978-3-319-67577-0","DOI":"10.1007\/978-3-319-67577-0"},{"key":"11718_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-2100-3","volume":"17","author":"D Damotte","year":"2019","unstructured":"Damotte D, Warren S, Arrondeau J et al (2019) The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Translational Med 17:1\u201310. https:\/\/doi.org\/10.1186\/s12967-019-2100-3","journal-title":"J Translational Med"},{"key":"11718_CR72","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3892\/ol.2020.11274","volume":"19","author":"W Jiang","year":"2020","unstructured":"Jiang W, Wang X, Zhang C et al (2020) Expression and clinical significance of MAPK and EGFR in triple\u2013negative breast cancer. Oncol Lett 19:1842\u20131848. https:\/\/doi.org\/10.3892\/ol.2020.11274","journal-title":"Oncol Lett"},{"key":"11718_CR73","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdm522","volume":"19","author":"Y Eralp","year":"2008","unstructured":"Eralp Y, Derin D, Ozluk Y et al (2008) MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19:669\u2013674. https:\/\/doi.org\/10.1093\/annonc\/mdm522","journal-title":"Ann Oncol"},{"key":"11718_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-018-0511-5","volume":"18","author":"L Jiang","year":"2018","unstructured":"Jiang L, Wang Y, Liu G et al (2018) C-Phycocyanin exerts anti-cancer effects via the MAPK signaling pathway in MDA-MB-231 cells. Cancer Cell Int 18:1\u201314. https:\/\/doi.org\/10.1186\/s12935-018-0511-5","journal-title":"Cancer Cell Int"},{"key":"11718_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01277-8","volume":"22","author":"C Perez Kerkvliet","year":"2020","unstructured":"Perez Kerkvliet C, Dwyer AR, Diep CH et al (2020) Glucocorticoid receptors are required effectors of TGF\u03b21-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer. Breast Cancer Res 22:1\u201323. https:\/\/doi.org\/10.1186\/s13058-020-01277-8","journal-title":"Breast Cancer Res"},{"key":"11718_CR76","doi-asserted-by":"publisher","first-page":"108249","DOI":"10.18632\/oncotarget.22604","volume":"8","author":"J Huang","year":"2017","unstructured":"Huang J, Luo Q, Xiao Y et al (2017) The implication from RAS\/RAF\/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. Oncotarget 8:108249\u2013108260. https:\/\/doi.org\/10.18632\/oncotarget.22604","journal-title":"Oncotarget"},{"key":"11718_CR77","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/CCO.0000000000000234","volume":"27","author":"D Bedognetti","year":"2015","unstructured":"Bedognetti D, Hendrickx W, Marincola FM, Miller LD (2015) Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol 27:433\u2013444. https:\/\/doi.org\/10.1097\/CCO.0000000000000234","journal-title":"Curr Opin Oncol"},{"key":"11718_CR78","doi-asserted-by":"publisher","unstructured":"Loi S, Dushyanthen S, Beavis PA et al (2019) Correction: RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499\u2009\u2013\u2009509) DOI: 10.1158. Clinical Cancer Research 25:1437. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4264","DOI":"10.1158\/1078-0432.CCR-18-4264"},{"key":"11718_CR79","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1158\/1078-0432.CCR-12-0274","volume":"19","author":"V Gordon","year":"2013","unstructured":"Gordon V, Banerji S (2013) Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res 19:3738\u20133744. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0274","journal-title":"Clin Cancer Res"},{"key":"11718_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/947858","author":"F Dituri","year":"2011","unstructured":"Dituri F, Mazzocca A, Giannelli G, Antonaci S (2011) PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol. https:\/\/doi.org\/10.1155\/2011\/947858","journal-title":"Clin Dev Immunol"},{"key":"11718_CR81","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","volume":"1851","author":"PT Hawkins","year":"2015","unstructured":"Hawkins PT, Stephens LR (2015) PI3K signalling in inflammation. Biochimica et Biophysica Acta - Molecular and Cell. Biology Lipids 1851:882\u2013897. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.006","journal-title":"Biology Lipids"},{"key":"11718_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G (2017) The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol 8:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2017.01124","journal-title":"Front Immunol"},{"key":"11718_CR83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","volume":"78","author":"T Maeda","year":"2018","unstructured":"Maeda T, Hiraki M, Jin C et al (2018) MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Res 78:205\u2013215. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1636","journal-title":"Cancer Res"},{"key":"11718_CR84","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1038\/leu.2017.163","volume":"31","author":"AR Pyzer","year":"2017","unstructured":"Pyzer AR, Stroopinsky D, Rosenblatt J et al (2017) MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 31:2780\u20132790. https:\/\/doi.org\/10.1038\/leu.2017.163","journal-title":"Leukemia"},{"key":"11718_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00386","volume":"8","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yue J et al (2018) Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: Beyond immune evasion. Front Oncol 8:1\u20138. https:\/\/doi.org\/10.3389\/fonc.2018.00386","journal-title":"Front Oncol"},{"key":"11718_CR86","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","volume":"4","author":"N Chalhoub","year":"2009","unstructured":"Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127\u2013150. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092311","journal-title":"Annu Rev Pathol"},{"key":"11718_CR87","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1038\/onc.2008.244","volume":"27","author":"L Zhao","year":"2008","unstructured":"Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486\u20135496. https:\/\/doi.org\/10.1038\/onc.2008.244","journal-title":"Oncogene"},{"key":"11718_CR88","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/bcr322","volume":"3","author":"T Petrocelli","year":"2001","unstructured":"Petrocelli T, Slingerland JM (2001) Commentary PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res 3:356\u2013360","journal-title":"Breast Cancer Res"},{"key":"11718_CR89","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/annonc\/mdh388","volume":"15","author":"La DeGraffenried","year":"2004","unstructured":"DeGraffenried La, Fulcher L, Friedrichs WE et al (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase\/Akt pathway. Annals oncology: official J Eur Soc Med Oncol \/ ESMO 15:1510\u20131516. https:\/\/doi.org\/10.1093\/annonc\/mdh388","journal-title":"Annals oncology: official J Eur Soc Med Oncol \/ ESMO"},{"key":"11718_CR90","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1073\/pnas.0702596104","volume":"104","author":"J Zhou","year":"2007","unstructured":"Zhou J, Wulfkuhle J, Zhang H et al (2007) Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104:16158\u201316163. https:\/\/doi.org\/10.1073\/pnas.0702596104","journal-title":"Proc Natl Acad Sci USA"},{"key":"11718_CR91","doi-asserted-by":"publisher","first-page":"31858","DOI":"10.1074\/jbc.C100271200","volume":"276","author":"R Chen","year":"2001","unstructured":"Chen R, Kim O, Yang J et al (2001) Regulation of Akt\/PKB Activation by Tyrosine Phosphorylation. J Biol Chem 276:31858\u201331862. https:\/\/doi.org\/10.1074\/jbc.C100271200","journal-title":"J Biol Chem"},{"key":"11718_CR92","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11515-017-1443-5","volume":"12","author":"A Brandmaier","year":"2017","unstructured":"Brandmaier A, Hou SQ, Demaria S et al (2017) PTEN at the interface of immune tolerance and tumor suppression. Front Biology 12:163\u2013174. https:\/\/doi.org\/10.1007\/s11515-017-1443-5","journal-title":"Front Biology"},{"key":"11718_CR93","doi-asserted-by":"publisher","first-page":"99901","DOI":"10.18632\/oncotarget.21914","volume":"8","author":"S Liu","year":"2017","unstructured":"Liu S, Chen S, Yuan W et al (2017) PD-1 \/ PD-L1 interaction up-regulates MDR1 \/ P-gp expression in breast cancer cells via PI3K \/ AKT and MAPK \/ ERK pathways. Oncotarget 8:99901\u201399912","journal-title":"Oncotarget"},{"key":"11718_CR94","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5952836","author":"Z Liu","year":"2019","unstructured":"Liu Z, Jiang Z, Gao Y et al (2019) TP53 mutations promote immunogenic activity in breast cancer. J Oncol. https:\/\/doi.org\/10.1155\/2019\/5952836","journal-title":"J Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11718-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11718-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11718-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:52:40Z","timestamp":1774950760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11718-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11718"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11718-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"559"}}